AzTrials
AzTrials

DeliriumDELIREANCT03125252

Impact of Non-pharmacological Prevention Measures on the Incidence of Delirium in Adult Intensive Care Units

A study testing Bundle and Standard Paramedical and Medical practices in people with Delirium, run by University Hospital, Toulouse at 14 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main objective is to evaluate the impact of the "bundle of actions" on the delirium's incidence in resuscitation patients during their stay in the service, compared to a conventional treatment. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Delirium
What is being tested?
Bundle and Standard Paramedical and Medical practices
Could I receive a placebo?
No, everyone receives an active treatment
How many people
379 participants
Where
14 sitesFrance
Study dates
27 Oct 2016to Nov 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed consent signed by the trusted person and the patient upon waking
  • Hospitalized in reanimation service (first hospitalization or transfer of another service)
  • 48 hours of sedation with intubation during hospitalization (all combinations of morphine, hypnotics, sedatives, anesthetics, narcoleptics)
  • Francophone (able to understand all evaluations)
  • Criteria for the inclusion of 50 delirium positive patients drawn from the Toulouse center (participating in the neuropsychological evaluation): In addition to those mentioned above:
  • Absence of pre-existing cognitive impairment (patients whose relative has completed the IQCode questionnaire and whose score is <3.4 points)
  • Visual, auditory (authorized equipment) skills and adequate oral or written expression for the proper conduct of neuropsychological tests.

Who cannot join

  • Pregnant women
  • Evolutive neurological disease leading to cognitive impairment (multiple sclerosis, Parkinson's disease, Alzheimer's disease), and / or focal neurological disease leading to cognitive impairment (head trauma, stroke, ...)
  • Evolving psychiatric illness (including severe depression)
  • Voluntary drug poisoning
  • Patients who have already participated in the study

Trial locations and contacts

14 sites in 1 country.

14 sites in 1 country

France14 sites
  • Saint-André Hospital

    Bordeaux, 33000

  • Hospital Castres-Mazamet

    Castres, 81

  • Estaing Hospital

    Clermont-Ferrand, 63100

  • Gabriel Montpied

    Clermont-Ferrand, 63100

  • Nord Hospital

    Marseille, 13015

  • Saint-Joseph Hospital

    Marseille, 13285

  • Montauban Hospital

    Montauban, 82000

  • Hospital

    Montpellier, 34090

  • Caremeau Hospital

    Nîmes, 30929

  • Perpignan Hospital

    Perpignan, 66046

  • Jacques Puel Hospital

    Rodez, 12027

  • University Hospital Toulouse

    Toulouse, 31000

  • Oncologic Hospital

    Toulouse, 31059

  • Rangueil Hospital

    Toulouse, 31059

Other trials in France

About this study

The main objective is to evaluate the impact of the "bundle of actions" on the delirium's incidence in resuscitation patients during their stay in the service, compared to a conventional treatment.

The investigators therefore hypothesize that a set of coordinated paramedical actions in the prevention of delirium would reduce its incidence by 15% compared to conventional care.

Read the detailed description

The "Bundle of Actions" is a coordinated and specific action plan, which has already been validated, focusing on the coordination of wake-up and respiration, the management of delirium, as well as the early mobility of the patient. Innovation consists of simple, reproducible nursing care that reduces triggers of delirium; as well as the use of two new approaches in reanimation: conversational hypnosis and early and comprehensive re-empowerment of the patient in the management of his pain and well-being.

Conditions
Delirium
Being tested
Bundle, Standard Paramedical and Medical practices
Keywords
Delirium, Reanimation, Conversational hypnosis
Medical subject headings
Delirium

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BundleOther

    Also called ABCDE

    Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility

    Factors of environment:

    • thirst
    • noise
    • pain and well-being
    • sleep
    • isolation
  • Standard Paramedical and Medical practicesOther

    The current recommendations recommend the following scheme:

    • Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)
    • Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)
    • Use of reference antipsychotic pharmacological means
Study groups in NCT03125252
Study groupRoleWhat they receive
BundleExperimentalSpecific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
Receives: Other: Bundle
ControlOtherStandard paramedical and medical practices
Receives: Other: Standard Paramedical and Medical practices

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence rate of delirium

    CAM-ICU Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scale.

    Measured: Day 60

Secondary outcomes (3)
  1. Duration of the delirium between the diagnosis and the resolution of the delirium

    The duration of the delirium (in days) between the diagnosis and the resolution of the delirium will be done until 60 days of the stay of the patients in intensive care.

    Measured: Day 60

  2. Evaluation of cognitive and psycho-behavioral functions.

    Cognitive and psycho-behavioral functions are usually evaluated by a corpus of test :

    • memory : Test of 5 words and Free Recall Test
    • executive : Fast Evaluation Battery for Executive Functions, Trail Making Test, Digit Span, Stroop and Verbal Fluences and Animals
    • praxis : Mahieux's Test
    • language : D0 80
    • behavior : Montgomery's scale (depression), Starkstein's scale (apathy).

    Measured: Day 60 and month 3

  3. Quality of life at one year

    The evaluation of 142 first patients delirium positive: the first 12 patients delirium positive in the 6 centers of the arm to which Toulouse will not belong, and the first 14 patients delirium positive in the 5 centers of the arm to which Toulouse will belong (Toulouse excluded), 1 year after the date of their inclusion in the study during their hospitalization in reanimation service.

    This evaluation of Quality of life of the first patients detected positive to delirium will be carried out using the validated French standardized questionnaire or Short Form 36 item (SF-36) which will be sent by post to the patient's home.

    Measured: Year 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2017
  2. Study start27 Oct 2016
  3. Primary completionApr 2020
  4. Study completionNov 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
379 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03125252
Sponsor's protocol ID
15 7842 16
Acronym
DELIREA
Status last verified
Nov 2020
First submitted
5 Mar 2017
Last updated
12 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Aissaoui Y, Zeggwagh AA, Zekraoui A, Abidi K, Abouqal R. Validation of a behavioral pain scale in critically ill, sedated, and mechanically ventilated patients. Anesth Analg. 2005 Nov;101(5):1470-1476. doi: 10.1213/01.ANE.0000182331.68722.FF.

    PubMed 16244013
  • Arend E, Christensen M. Delirium in the intensive care unit: a review. Nurs Crit Care. 2009 May-Jun;14(3):145-54. doi: 10.1111/j.1478-5153.2008.00324.x.

    PubMed 19366412
  • Balas MC, Vasilevskis EE, Burke WJ, Boehm L, Pun BT, Olsen KM, Peitz GJ, Ely EW. Critical care nurses' role in implementing the "ABCDE bundle" into practice. Crit Care Nurse. 2012 Apr;32(2):35-8, 40-7; quiz 48. doi: 10.4037/ccn2012229.

    PubMed 22467611
  • Chanques G, Payen JF, Mercier G, de Lattre S, Viel E, Jung B, Cisse M, Lefrant JY, Jaber S. Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale. Intensive Care Med. 2009 Dec;35(12):2060-7. doi: 10.1007/s00134-009-1590-5.

    PubMed 19697008
  • Devlin JW, Brummel NE, Al-Qadheeb NS. Optimising the recognition of delirium in the intensive care unit. Best Pract Res Clin Anaesthesiol. 2012 Sep;26(3):385-93. doi: 10.1016/j.bpa.2012.08.002.

    PubMed 23040288
  • Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62. doi: 10.1001/jama.291.14.1753.

    PubMed 15082703
  • Erickson MH, Rossi EL. Two level communication and the microdynamics of trance and suggestion. Am J Clin Hypn. 1976 Jan;18(3):153-71. doi: 10.1080/00029157.1976.10403794. No abstract available.

    PubMed 1246970
  • Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Crit Care. 2008;12 Suppl 3(Suppl 3):S3. doi: 10.1186/cc6149. Epub 2008 May 14.

    PubMed 18495054
  • Guenther U, Popp J, Koecher L, Muders T, Wrigge H, Ely EW, Putensen C. Validity and reliability of the CAM-ICU Flowsheet to diagnose delirium in surgical ICU patients. J Crit Care. 2010 Mar;25(1):144-51. doi: 10.1016/j.jcrc.2009.08.005. Epub 2009 Oct 13.

    PubMed 19828283
  • McCusker J, Cole MG, Voyer P, Monette J, Champoux N, Ciampi A, Vu M, Belzile E. Six-month outcomes of co-occurring delirium, depression, and dementia in long-term care. J Am Geriatr Soc. 2014 Dec;62(12):2296-302. doi: 10.1111/jgs.13159. Epub 2014 Dec 8.

    PubMed 25482152
  • Crozes F, Seailles S, Planton M, Lepage M, Quintard M, Huo Yung Kai S, Silva S, Haubertin C. Impact des mesures preventives non pharmacologiques sur l'incidence du delirium chez les adultes en reanimation : protocole d'etude d'un essai controle randomise en cluster. Rech Soins Infirm. 2026;164(1):57-70. doi: 10.3917/rsi.164.0057. French.

    PubMed 42686628

Questions about this trial

What is this clinical trial studying?

A study testing Bundle and Standard Paramedical and Medical practices in people with Delirium, run by University Hospital, Toulouse at 14 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence rate of delirium (time frame: Day 60). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03125252, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in